Liam Kelly
Liam Kelly's purchase track record
Liam Kelly has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/5/2025 | TFX | $173K | +8.6% | -10.3% | +9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate. Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.
Transaction History
| ENOV | ▲ Buy | Grant | 9,346 | $0 | 5/19/2026 | View on chart |
| TFX | ▲ Buy | Open Market | 1,500 | $173K | 8/5/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 6,598 | $0 | 5/21/2025 | View on chart |
| TFX | ▲ Buy | Grant | 10,195 | $0 | 3/4/2025 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 2,081 | $276K | 3/1/2025 | View on chart |
| TFX | ▲ Buy | Grant | 1,317 | $0 | 2/24/2025 | View on chart |
| TFX | ▲ Buy | Option Exercise | 29,084 | $3.5M | 2/19/2025 | View on chart |
| TFX | ▲ Buy | Option Exercise | 7,380 | $908K | 2/19/2025 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 29,220 | $5.0M | 2/19/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 4,338 | $0 | 5/20/2024 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 1,840 | $410K | 3/2/2024 | View on chart |
| TFX | ▲ Buy | Grant | 6,787 | $0 | 2/27/2024 | View on chart |
| TFX | ▲ Buy | Grant | 1,856 | $0 | 2/19/2024 | View on chart |
| TFX | ▲ Buy | Option Exercise | 23,175 | $2.3M | 12/27/2023 | View on chart |
| TFX | ▼ Sell | Open Market | 23,585 | $5.9M | 12/27/2023 | View on chart |
| TFX | ▲ Buy | Option Exercise | 3,081 | $331K | 12/27/2023 | View on chart |
| TFX | ▼ Sell | Open Market | 2,671 | $671K | 12/27/2023 | View on chart |
| TFX | ▼ Sell | Gift | 5,786 | $0 | 12/21/2023 | View on chart |
| TFX | ▼ Sell | Gift | 5,786 | $0 | 12/21/2023 | View on chart |
| TFX | ▼ Sell | Gift | 5,768 | $0 | 8/9/2023 | View on chart |
| TFX | ▼ Sell | Gift | 5,768 | $0 | 8/9/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 1,875 | $0 | 5/16/2023 | View on chart |
| TFX | ▲ Buy | Grant | 5,050 | $0 | 2/28/2023 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 1,025 | $241K | 2/25/2023 | View on chart |
| TFX | ▲ Buy | Option Exercise | 6,040 | $475K | 1/11/2023 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 3,622 | $940K | 1/11/2023 | View on chart |
| TFX | ▲ Buy | Option Exercise | 3,579 | $294K | 1/11/2023 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 2,173 | $564K | 1/11/2023 | View on chart |
| TFX | ▲ Buy | Option Exercise | 16,343 | $1.3M | 12/30/2022 | View on chart |
| TFX | ▼ Sell | Open Market | 16,340 | $4.1M | 12/30/2022 | View on chart |
| TFX | ▼ Sell | Open Market | 3 | $753 | 12/30/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 1,648 | $0 | 6/7/2022 | View on chart |
| TFX | ▲ Buy | Grant | 4,766 | $0 | 3/1/2022 | View on chart |
| TFX | ▼ Sell | Tax Withholding | 1,244 | $427K | 2/28/2022 | View on chart |
| TFX | ▲ Buy | Grant | 33 | $0 | 2/28/2022 | View on chart |
| TFX | ▲ Buy | Option Exercise | 2,276 | $136K | 12/27/2021 | View on chart |
| TFX | ▲ Buy | Option Exercise | 6,711 | $402K | 12/27/2021 | View on chart |
| TFX | ▼ Sell | Open Market | 8,987 | $3.0M | 12/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Enovis Gathers Fresh Attention After Reaffirming 2026 Guidance
Enovis has attracted new interest as analysts discuss its 2026 outlook. A recent review lowered the price target to $34 while maintaining a positive stance. The stock is trading near the top of its 52‑week range, and recent signals show a breakout and positive RSI divergence. These developments may influence how investors view the company’s valuation.
Enovis Gathers Fresh Attention After Reaffirming 2026 Guidance. Enovis has attracted new interest as analysts discuss its 2026 outlook. A recent review lowered the price target to $34 while maintaining a positive stance. The stock is trading near the top of its 52‑week range, and recent signals show a breakout and positive RSI divergence. These developments may influence how investors view the company’s valuation.